AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10919416 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (1.5 mg x kg(‐1) bolus over 15 min, followed by 10 microg x kg(‐1) x min(‐1) infusion)
Number of subjects: 234
Study 10919416 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal volume bolus followed by placebo infusion)
Number of subjects: 234
Study 8979280 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapiprazole 0.5% eye drops administered 3 times daily as adjunctive therapy to timolol 0.5% eye drops twice daily
Number of subjects: 16
Study 8979280 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% eye drops alone
Number of subjects: 16
Study 1461951 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 676
Study 6723452 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention program focusing on modeling verbal interaction between mother and child around selected toys and books
Number of subjects: 4
Study 6723452 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation with toys and books supplied without home visits
Number of subjects: 4
Study 6723452 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison treatments)
Number of subjects: 4
Study 31562406 — intervention group
Group type: EXPERIMENTAL
Intervention: Short tailored alcohol-related advice tool and leaflet
Number of subjects: 12
Study 31562406 — intervention group
Group type: COMPARATOR
Intervention: Mouth cancer prevention leaflet only (Control)
Number of subjects: 12
Study 30387335 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) after surgical excision and radiotherapy
Number of subjects: 240
Study 30387335 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision and radiotherapy only (Control group)
Number of subjects: 240
Study 27339806 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg folic acid, 25 mg Vitamin B6, and Vitamin B12
Number of subjects: 300
Study 24365797 — intervention group
Group type: EXPERIMENTAL
Intervention: COH-IVF
Number of subjects: 194
Study 24365797 — intervention group
Group type: COMPARATOR
Intervention: MNC-IVF
Number of subjects: 194
Study 24365797 — intervention group
Group type: COMPARATOR
Intervention: Sub-NC
Number of subjects: 194
Study 22152083 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) walking with elastic knee wraps
Number of subjects: 0
Study 22152083 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) walking without blood flow restriction
Number of subjects: 0
Study 20625068 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta‐1a (30 micrograms once weekly for 2 years)
Number of subjects: 160
Study 20625068 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once weekly for 2 years)
Number of subjects: 160
Study 18565107 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (3000 mg/day)
Number of subjects: 27
Study 18565107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 15731564 — intervention group
Group type: EXPERIMENTAL
Intervention: Superflux cellulose triacetate (CTA; Tricea 150G)
Number of subjects: 4
Study 15731564 — intervention group
Group type: COMPARATOR
Intervention: Low-flux polysulfone (PS; F 6HPS)
Number of subjects: 4
Study 15731564 — intervention group
Group type: COMPARATOR
Intervention: High-flux PS (F 60S)
Number of subjects: 4
Study 15731564 — intervention group
Group type: COMPARATOR
Intervention: Superflux PS (F 500S)
Number of subjects: 4
Study 11791150 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of sucrose (2160 kJ, 575 ml)
Number of subjects: 6
Study 11791150 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of maltose (2160 kJ, 575 ml)
Number of subjects: 6
Study 11791150 — intervention group
Group type: COMPARATOR
Intervention: Water control (67 kJ, 575 ml)
Number of subjects: 6
Study 11791150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric infusion of sucrose
Number of subjects: 6
Study 11791150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric infusion of maltose
Number of subjects: 6
Study 9935120 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton Thorne Research integrated visual optical system semen analyzers
Number of subjects: 30
Study 8534464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 10 micrograms
Number of subjects: 15
Study 8534464 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal normal saline (control)
Number of subjects: 15
Study 2178534 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of warfarin, beginning 3 days before catheter insertion and continuing for 90 days
Number of subjects: 121
Study 2178534 — intervention group
Group type: COMPARATOR
Intervention: No warfarin
Number of subjects: 121
Study 6988929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate
Number of subjects: 0
Study 6988929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31272930 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide once weekly
Number of subjects: 0
Study 31272930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28479118 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg/day)
Number of subjects: 72
Study 28479118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 25434633 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular catheter insertion for management of malignant ascites
Number of subjects: 55
Study 25434633 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular catheter insertion for management of lymphocysts
Number of subjects: 55
Study 25434633 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular catheter for patients with chronic ascites
Number of subjects: 55
Study 25434633 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular catheter for patients before primary cytoreduction for ovarian cancer
Number of subjects: 55
Study 23580599 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity isometric resistance training for 4 weeks
Number of subjects: 14
Study 23580599 — intervention group
Group type: COMPARATOR
Intervention: Nontraining control group
Number of subjects: 14
Study 21258206 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with percutaneous microwave ablation (PMWA) and adoptive immunotherapy
Number of subjects: 10
Study 19751500 — intervention group
Group type: EXPERIMENTAL
Intervention: Information program with specific procedural, sensory and coping information about their ICU stay
Number of subjects: 0
Study 19751500 — intervention group
Group type: COMPARATOR
Intervention: Trivial conversation without any ICU‐specific information
Number of subjects: 0
Study 17331963 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 800 microg/day
Number of subjects: 1175
Study 17331963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1175
Study 16371870 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR Berna vaccine
Number of subjects: 467
Study 16371870 — intervention group
Group type: COMPARATOR
Intervention: Licensed vaccine M-M-R-Vax (Merck & Co.)
Number of subjects: 467
Study 12526191 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine-derived bone protein extract with 12.5 micrograms/mg DFDBA
Number of subjects: 25
Study 12526191 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine-derived bone protein extract with 25.0 micrograms/mg DFDBA
Number of subjects: 25
Study 9594863 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO) at 40 ppm added to the oxygenator sweep gas
Number of subjects: 20
Study 9594863 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NO treatment)
Number of subjects: 20
Study 7879322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraurethral administration of prostaglandin E1
Number of subjects: 0
Study 7879322 — intervention group
Group type: COMPARATOR
Intervention: Intracavernous administration of half the dose of prostaglandin E1
Number of subjects: 0
Study 2242101 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled coffee (BC)
Number of subjects: 41
Study 2242101 — intervention group
Group type: COMPARATOR
Intervention: Filtered coffee (FC)
Number of subjects: 41
Study 227069 — intervention group
Group type: EXPERIMENTAL
Intervention: econazole-triamcinolon combination
Number of subjects: 58
Study 227069 — intervention group
Group type: COMPARATOR
Intervention: econazole
Number of subjects: 58
Study 30958012 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Intervention (MI)
Number of subjects: 0
Study 30958012 — intervention group
Group type: COMPARATOR
Intervention: Brief advice (Control)
Number of subjects: 0
Study 28043669 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning with postconditioning (RIPC with RIPostC)
Number of subjects: 1280
Study 28043669 — intervention group
Group type: COMPARATOR
Intervention: Sham (control)
Number of subjects: 1280
Study 25366707 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologist adjustments to screen results
Number of subjects: 3318
Study 24224396 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser fiber
Number of subjects: 45
Study 24224396 — intervention group
Group type: COMPARATOR
Intervention: Cold knife
Number of subjects: 45
Study 21464455 — intervention group
Group type: EXPERIMENTAL
Intervention: VCT at bars
Number of subjects: 591
Study 21464455 — intervention group
Group type: EXPERIMENTAL
Intervention: VCT at church
Number of subjects: 591
Study 21464455 — intervention group
Group type: COMPARATOR
Intervention: VCT at health centre
Number of subjects: 591
Study 20002082 — intervention group
Group type: EXPERIMENTAL
Intervention: LC15-0444 200 mg
Number of subjects: 30
Study 20002082 — intervention group
Group type: EXPERIMENTAL
Intervention: LC15-0444 400 mg
Number of subjects: 30
Study 20002082 — intervention group
Group type: EXPERIMENTAL
Intervention: LC15-0444 600 mg
Number of subjects: 30
Study 20002082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16804951 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study 16804951 — intervention group
Group type: EXPERIMENTAL
Intervention: PRRs (Proportional Reporting Ratios)
Number of subjects: 0
Study 14994729 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid thromboarterectomy
Number of subjects: 0
Study 14994729 — intervention group
Group type: COMPARATOR
Intervention: Carotid stenting
Number of subjects: 0
Study 10807761 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) with 2 mg estradiol + 1 mg norethisterone
Number of subjects: 42
Study 10807761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 8923067 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA with dipyrone (initially 2.0 g i.v. and 1.0 g/2 ml i.v. at 4, 8 and 16 h)
Number of subjects: 106
Study 8923067 — intervention group
Group type: COMPARATOR
Intervention: PCA with placebo (saline)
Number of subjects: 106
Study 8923067 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study 1366330 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginete pills with diet
Number of subjects: 0
Study 1366330 — intervention group
Group type: COMPARATOR
Intervention: Individual reduction diet
Number of subjects: 0
Study 6687341 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-taught curriculum
Number of subjects: 1081
Study 6687341 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult-taught curriculum
Number of subjects: 1081
Study 6687341 — intervention group
Group type: COMPARATOR
Intervention: Control school
Number of subjects: 1081
Study 30578894 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-weeks supervised moderate exercise program
Number of subjects: 34
Study 30578894 — intervention group
Group type: COMPARATOR
Intervention: Waitlist, control condition
Number of subjects: 34
Study 28957833 — intervention group
Group type: EXPERIMENTAL
Intervention: PureMoist
Number of subjects: 0
Study 28957833 — intervention group
Group type: EXPERIMENTAL
Intervention: RevitaLens
Number of subjects: 0
Study 28957833 — intervention group
Group type: COMPARATOR
Intervention: Clear Care (CC)
Number of subjects: 0
Study 28957833 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotrue
Number of subjects: 0
Study 28957833 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline Solution (SS)
Number of subjects: 0
Study 28957833 — intervention group
Group type: EXPERIMENTAL
Intervention: RevitaLens (RL)
Number of subjects: 0
Study 26396165 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory dynamic orthosis sleeve
Number of subjects: 21
Study 26396165 — intervention group
Group type: COMPARATOR
Intervention: Non-compressive sleeve (placebo)
Number of subjects: 21
Study 25335348 — intervention group
Group type: EXPERIMENTAL
Intervention: N2 jet cryotherapy once a week for 12 weeks
Number of subjects: 40
Study 25335348 — intervention group
Group type: COMPARATOR
Intervention: Topical 0.05% clobetasol proprionate lotion
Number of subjects: 40
Study 23106924 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 0
Study 23106924 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study 23106924 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary focus
Number of subjects: 0
Study 23106924 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple sites
Number of subjects: 0
Study 23106924 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible study design
Number of subjects: 0
Study 23106924 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive staff management
Number of subjects: 0
Study 23106924 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol implementation
Number of subjects: 0
Study 23106924 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely data tracking
Number of subjects: 0
Study 23106924 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex multi-site trials
Number of subjects: 0
Study 20576091 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30‐70 mg/d
Number of subjects: 127
Study 20576091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 20576091 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 127
Study 18584266 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussing a negative personal experience
Number of subjects: 216
Study 18584266 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussing a positive personal experience
Number of subjects: 216
Study 18584266 — intervention group
Group type: EXPERIMENTAL
Intervention: High hostility individuals
Number of subjects: 216
Study 18584266 — intervention group
Group type: EXPERIMENTAL
Intervention: Support recipients and providers
Number of subjects: 216
Study 16061764 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (paroxetine hydrochloride or bupropion hydrochloride)
Number of subjects: 267
Study 16061764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 267
Study 16061764 — intervention group
Group type: COMPARATOR
Intervention: Community Referral
Number of subjects: 267
Study 11949768 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 mg)
Number of subjects: 10
Study 11949768 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 10
Study 11949768 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (15 mg)
Number of subjects: 10
Study 11949768 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (30 mg)
Number of subjects: 10
Study 11949768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg) + Triazolam
Number of subjects: 10
Study 11949768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg) + Temazepam
Number of subjects: 10
Study 11949768 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0 g/kg)
Number of subjects: 10
Study 11949768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10349927 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2% via lumbar epidural block
Number of subjects: 28
Study 10349927 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 0.25% (0.7 ml x kg(‐1)) via lumbar epidural block
Number of subjects: 28
Study 7572122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine injection (1 mg/kg)
Number of subjects: 30
Study 2163814 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin for a maximum of 10 weeks
Number of subjects: 1476
Study 2163814 — intervention group
Group type: COMPARATOR
Intervention: Placebo for a maximum of 10 weeks
Number of subjects: 1476
Study 795441 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol HCl 10 g twice daily
Number of subjects: 66
Study 795441 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 66
Study 795441 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol HCl
Number of subjects: 66
Study 795441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 31640694 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-Based Financing (PBF) intervention
Number of subjects: 0
Study 31640694 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (quasi-experimental design)
Number of subjects: 0
Study 24916207 — intervention group
Group type: EXPERIMENTAL
Intervention: Job aids-focused intervention
Number of subjects: 411
Study 24916207 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 411
Study 22534451 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP)
Number of subjects: 0
Study 22534451 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (control group)
Number of subjects: 0
Study 20650587 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-s injection duration
Number of subjects: 116
Study 20650587 — intervention group
Group type: COMPARATOR
Intervention: 35-s injection duration
Number of subjects: 116
Study 20650587 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 116
Study 18806924 — intervention group
Group type: EXPERIMENTAL
Intervention: Change detection with peripheral faces changing to joy, anger, or disgust during the visual letter task.
Number of subjects: 0
Study 18806924 — intervention group
Group type: EXPERIMENTAL
Intervention: Change to disgust as a specific emotion expression change.
Number of subjects: 0
Study 18806924 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit change detection during the tasks.
Number of subjects: 0
Study 22298019 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal GTN (0.6 mg/h) for 2 h a day for 6 days
Number of subjects: 30
Study 22298019 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PETN (80 mg) once a day for 6 days
Number of subjects: 30
Study 22298019 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 30
Study 15900289 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg AZD3582
Number of subjects: 60
Study 15900289 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg AZD3582
Number of subjects: 60
Study 15900289 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg rofecoxib
Number of subjects: 60
Study 15900289 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg naproxen
Number of subjects: 60
Study 15900289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12576917 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: three 8‐mg doses of ondansetron intravenously at 4‐hour intervals plus dexamethasone 20 mg intravenously from the start of chemotherapy, followed by dexamethasone 5 mg intravenously every 12 hours.
Number of subjects: 400
Study 12576917 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B: three 8‐mg doses of ondansetron intravenously at 24‐hour intervals plus dexamethasone as in Arm A.
Number of subjects: 400
Study 12576917 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete control of vomiting/nausea for patients without emesis during previous cycles.
Number of subjects: 400
Study 12576917 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients during chemotherapy cycles.
Number of subjects: 400
Study 9609084 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab treatment
Number of subjects: 638
Study 9609084 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab with standard-dose heparin
Number of subjects: 638
Study 7707848 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorectal advancement flap (group A, n = 34)
Number of subjects: 55
Study 7707848 — intervention group
Group type: COMPARATOR
Intervention: Mucosal flap (group B, n = 21)
Number of subjects: 55
Study 2760974 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice powder electrolyte solution
Number of subjects: 30
Study 2760974 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose electrolyte solution
Number of subjects: 30
Study 899804 — intervention group
Group type: EXPERIMENTAL
Intervention: High or low tones without requirement for motor response
Number of subjects: 0
Study 899804 — intervention group
Group type: EXPERIMENTAL
Intervention: High or low tones with requirement of motor response
Number of subjects: 0
Study 899804 — intervention group
Group type: EXPERIMENTAL
Intervention: Identical number of high and low tones in random order with requirement of motor response to only 1
Number of subjects: 0
Study 899804 — intervention group
Group type: EXPERIMENTAL
Intervention: Only high tones with instruction that both tones will appear in random order and requirement for motor response to one
Number of subjects: 0
Study 899804 — intervention group
Group type: COMPARATOR
Intervention: All series of stimuli
Number of subjects: 0
Study 12715722 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (recombinant IL-1 receptor antagonist) with or without methotrexate
Number of subjects: 0
Study 29795141 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA 2.5-4 ng/mL
Number of subjects: 1534
Study 29795141 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA 4.1-6 ng/mL
Number of subjects: 1534
Study 29795141 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA 6-10 ng/mL
Number of subjects: 1534
Study 27475817 — intervention group
Group type: EXPERIMENTAL
Intervention: Retromuscular polypropylene mesh
Number of subjects: 86
Study 27475817 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-row plication with Quill technology
Number of subjects: 86